Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature

Pharmacogenomic screening can identify patients with gene variants that predispose them to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of the critical metabolic enzyme dihydropyrimidine dehydrogenase (DPD) leads to excessive toxicity on exposure to fluoropy...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics and personalized medicine 2021-01, Vol.14, p.1603-1617
Main Authors: White, Cassandra, Scott, Rodney J, Paul, Christine, Ziolkowski, Andrew, Mossman, David, Ackland, Stephen
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Chemotherapy
Dehydrogenases
dihydropyrimidine dehydrogenase
dpyd gene
Enzymes
Genes
Genotypes
Investigations
Literature reviews
Metabolism
Metabolites
Multiculturalism
Multiculturalism & pluralism
non-caucasian
Patients
Pharmacogenetics
Pharmacogenomics
Review
Toxicity
White people
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c576t-9ccb0dd622f3a6fb3495333220c5eacf8cdee08b3dcb8fa2942c4c4de5b45ec3
cites cdi_FETCH-LOGICAL-c576t-9ccb0dd622f3a6fb3495333220c5eacf8cdee08b3dcb8fa2942c4c4de5b45ec3
container_end_page 1617
container_issue
container_start_page 1603
container_title Pharmacogenomics and personalized medicine
container_volume 14
creator White, Cassandra
Scott, Rodney J
Paul, Christine
Ziolkowski, Andrew
Mossman, David
Ackland, Stephen
description Pharmacogenomic screening can identify patients with gene variants that predispose them to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of the critical metabolic enzyme dihydropyrimidine dehydrogenase (DPD) leads to excessive toxicity on exposure to fluoropyrimidine chemotherapy. This can result in hospitalisation, intensive care admissions and even death. Upfront screening of the gene that encodes for DPD ( ) has recently been implemented in regions throughout Europe and the United Kingdom. Current screening evaluates variants that are well described within Caucasian patient populations and provides genotyped-guided dose adjustment recommendations based upon the presence of these variants. This article reviews the differences in gene variants within non-Caucasian populations compared to Caucasian populations, with regard to the implications for clinical tolerance of fluoropyrimidine chemotherapies and genotype guided dose adjustment guidelines.
doi_str_mv 10.2147/PGPM.S337147
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_51637a067bf64330bea46a582b059405</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A689558203</galeid><doaj_id>oai_doaj_org_article_51637a067bf64330bea46a582b059405</doaj_id><sourcerecordid>A689558203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-9ccb0dd622f3a6fb3495333220c5eacf8cdee08b3dcb8fa2942c4c4de5b45ec3</originalsourceid><addsrcrecordid>eNptkk2P0zAQhiMEYpeFG2cUCQlxoMUfsZNwQKq2S1mpiAr2wslynHHjKrUX2ynaf4-zLUuLkA_2zDzzejyeLHuJ0ZTgony_Wqy-TL9TWibjUXaOcVlNSsT546PzWfYshA1Kp4qSp9kZLWrMK1KfZ8ur2Fmj8rnZgQ8m3uVO5_PVPJ-paHajLW2bxw6S88c8X4CFD_k32Bn4NZJjYGkieBkHD8-zJ1r2AV4c9ovs5tPVzeXnyfLr4vpytpwoVvI4qZVqUNtyQjSVXDepGkYpJQQpBlLpSrUAqGpoq5pKS1IXRBWqaIE1BQNFL7LrvWzr5EbcerOV_k44acS9w_m1kD4a1YNgmNNSIl42mheUogZkwSWrSINYXSCWtD7utW6HZgutAhu97E9ETyPWdGLtdqJKvSSsTAJvDwLe_RwgRLE1QUHfSwtuCIJwjDmrClwn9PU_6MYN3qZO3VPpe1KFf6m1TA8wVrt0rxpFxYxXNUvFI5qo6X-otFrYGuUsaJP8JwlvjhI6kH3sguuHaJwNp-C7Pai8C8GDfmgGRmKcODFOnDhMXMJfHTfwAf4zYvQ3AIrNXQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2611006330</pqid></control><display><type>article</type><title>Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content (ProQuest)</source><creator>White, Cassandra ; Scott, Rodney J ; Paul, Christine ; Ziolkowski, Andrew ; Mossman, David ; Ackland, Stephen</creator><creatorcontrib>White, Cassandra ; Scott, Rodney J ; Paul, Christine ; Ziolkowski, Andrew ; Mossman, David ; Ackland, Stephen</creatorcontrib><description>Pharmacogenomic screening can identify patients with gene variants that predispose them to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of the critical metabolic enzyme dihydropyrimidine dehydrogenase (DPD) leads to excessive toxicity on exposure to fluoropyrimidine chemotherapy. This can result in hospitalisation, intensive care admissions and even death. Upfront screening of the gene that encodes for DPD ( ) has recently been implemented in regions throughout Europe and the United Kingdom. Current screening evaluates variants that are well described within Caucasian patient populations and provides genotyped-guided dose adjustment recommendations based upon the presence of these variants. This article reviews the differences in gene variants within non-Caucasian populations compared to Caucasian populations, with regard to the implications for clinical tolerance of fluoropyrimidine chemotherapies and genotype guided dose adjustment guidelines.</description><identifier>ISSN: 1178-7066</identifier><identifier>EISSN: 1178-7066</identifier><identifier>DOI: 10.2147/PGPM.S337147</identifier><identifier>PMID: 34916829</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Cancer ; Cancer therapies ; Chemotherapy ; Dehydrogenases ; dihydropyrimidine dehydrogenase ; dpyd gene ; Enzymes ; Genes ; Genotypes ; Investigations ; Literature reviews ; Metabolism ; Metabolites ; Multiculturalism ; Multiculturalism &amp; pluralism ; non-caucasian ; Patients ; Pharmacogenetics ; Pharmacogenomics ; Review ; Toxicity ; White people</subject><ispartof>Pharmacogenomics and personalized medicine, 2021-01, Vol.14, p.1603-1617</ispartof><rights>2021 White et al.</rights><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 White et al. 2021 White et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c576t-9ccb0dd622f3a6fb3495333220c5eacf8cdee08b3dcb8fa2942c4c4de5b45ec3</citedby><cites>FETCH-LOGICAL-c576t-9ccb0dd622f3a6fb3495333220c5eacf8cdee08b3dcb8fa2942c4c4de5b45ec3</cites><orcidid>0000-0001-5268-2793</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2611006330/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2611006330?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34916829$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>White, Cassandra</creatorcontrib><creatorcontrib>Scott, Rodney J</creatorcontrib><creatorcontrib>Paul, Christine</creatorcontrib><creatorcontrib>Ziolkowski, Andrew</creatorcontrib><creatorcontrib>Mossman, David</creatorcontrib><creatorcontrib>Ackland, Stephen</creatorcontrib><title>Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature</title><title>Pharmacogenomics and personalized medicine</title><addtitle>Pharmgenomics Pers Med</addtitle><description>Pharmacogenomic screening can identify patients with gene variants that predispose them to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of the critical metabolic enzyme dihydropyrimidine dehydrogenase (DPD) leads to excessive toxicity on exposure to fluoropyrimidine chemotherapy. This can result in hospitalisation, intensive care admissions and even death. Upfront screening of the gene that encodes for DPD ( ) has recently been implemented in regions throughout Europe and the United Kingdom. Current screening evaluates variants that are well described within Caucasian patient populations and provides genotyped-guided dose adjustment recommendations based upon the presence of these variants. This article reviews the differences in gene variants within non-Caucasian populations compared to Caucasian populations, with regard to the implications for clinical tolerance of fluoropyrimidine chemotherapies and genotype guided dose adjustment guidelines.</description><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Dehydrogenases</subject><subject>dihydropyrimidine dehydrogenase</subject><subject>dpyd gene</subject><subject>Enzymes</subject><subject>Genes</subject><subject>Genotypes</subject><subject>Investigations</subject><subject>Literature reviews</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Multiculturalism</subject><subject>Multiculturalism &amp; pluralism</subject><subject>non-caucasian</subject><subject>Patients</subject><subject>Pharmacogenetics</subject><subject>Pharmacogenomics</subject><subject>Review</subject><subject>Toxicity</subject><subject>White people</subject><issn>1178-7066</issn><issn>1178-7066</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk2P0zAQhiMEYpeFG2cUCQlxoMUfsZNwQKq2S1mpiAr2wslynHHjKrUX2ynaf4-zLUuLkA_2zDzzejyeLHuJ0ZTgony_Wqy-TL9TWibjUXaOcVlNSsT546PzWfYshA1Kp4qSp9kZLWrMK1KfZ8ur2Fmj8rnZgQ8m3uVO5_PVPJ-paHajLW2bxw6S88c8X4CFD_k32Bn4NZJjYGkieBkHD8-zJ1r2AV4c9ovs5tPVzeXnyfLr4vpytpwoVvI4qZVqUNtyQjSVXDepGkYpJQQpBlLpSrUAqGpoq5pKS1IXRBWqaIE1BQNFL7LrvWzr5EbcerOV_k44acS9w_m1kD4a1YNgmNNSIl42mheUogZkwSWrSINYXSCWtD7utW6HZgutAhu97E9ETyPWdGLtdqJKvSSsTAJvDwLe_RwgRLE1QUHfSwtuCIJwjDmrClwn9PU_6MYN3qZO3VPpe1KFf6m1TA8wVrt0rxpFxYxXNUvFI5qo6X-otFrYGuUsaJP8JwlvjhI6kH3sguuHaJwNp-C7Pai8C8GDfmgGRmKcODFOnDhMXMJfHTfwAf4zYvQ3AIrNXQ</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>White, Cassandra</creator><creator>Scott, Rodney J</creator><creator>Paul, Christine</creator><creator>Ziolkowski, Andrew</creator><creator>Mossman, David</creator><creator>Ackland, Stephen</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>KB0</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5268-2793</orcidid></search><sort><creationdate>20210101</creationdate><title>Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature</title><author>White, Cassandra ; Scott, Rodney J ; Paul, Christine ; Ziolkowski, Andrew ; Mossman, David ; Ackland, Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-9ccb0dd622f3a6fb3495333220c5eacf8cdee08b3dcb8fa2942c4c4de5b45ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Dehydrogenases</topic><topic>dihydropyrimidine dehydrogenase</topic><topic>dpyd gene</topic><topic>Enzymes</topic><topic>Genes</topic><topic>Genotypes</topic><topic>Investigations</topic><topic>Literature reviews</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Multiculturalism</topic><topic>Multiculturalism &amp; pluralism</topic><topic>non-caucasian</topic><topic>Patients</topic><topic>Pharmacogenetics</topic><topic>Pharmacogenomics</topic><topic>Review</topic><topic>Toxicity</topic><topic>White people</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>White, Cassandra</creatorcontrib><creatorcontrib>Scott, Rodney J</creatorcontrib><creatorcontrib>Paul, Christine</creatorcontrib><creatorcontrib>Ziolkowski, Andrew</creatorcontrib><creatorcontrib>Mossman, David</creatorcontrib><creatorcontrib>Ackland, Stephen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Pharmacogenomics and personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>White, Cassandra</au><au>Scott, Rodney J</au><au>Paul, Christine</au><au>Ziolkowski, Andrew</au><au>Mossman, David</au><au>Ackland, Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature</atitle><jtitle>Pharmacogenomics and personalized medicine</jtitle><addtitle>Pharmgenomics Pers Med</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>14</volume><spage>1603</spage><epage>1617</epage><pages>1603-1617</pages><issn>1178-7066</issn><eissn>1178-7066</eissn><abstract>Pharmacogenomic screening can identify patients with gene variants that predispose them to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of the critical metabolic enzyme dihydropyrimidine dehydrogenase (DPD) leads to excessive toxicity on exposure to fluoropyrimidine chemotherapy. This can result in hospitalisation, intensive care admissions and even death. Upfront screening of the gene that encodes for DPD ( ) has recently been implemented in regions throughout Europe and the United Kingdom. Current screening evaluates variants that are well described within Caucasian patient populations and provides genotyped-guided dose adjustment recommendations based upon the presence of these variants. This article reviews the differences in gene variants within non-Caucasian populations compared to Caucasian populations, with regard to the implications for clinical tolerance of fluoropyrimidine chemotherapies and genotype guided dose adjustment guidelines.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>34916829</pmid><doi>10.2147/PGPM.S337147</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-5268-2793</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-7066
ispartof Pharmacogenomics and personalized medicine, 2021-01, Vol.14, p.1603-1617
issn 1178-7066
1178-7066
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_51637a067bf64330bea46a582b059405
source Open Access: PubMed Central; Taylor & Francis Open Access; Publicly Available Content (ProQuest)
subjects Cancer
Cancer therapies
Chemotherapy
Dehydrogenases
dihydropyrimidine dehydrogenase
dpyd gene
Enzymes
Genes
Genotypes
Investigations
Literature reviews
Metabolism
Metabolites
Multiculturalism
Multiculturalism & pluralism
non-caucasian
Patients
Pharmacogenetics
Pharmacogenomics
Review
Toxicity
White people
title Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T20%3A40%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ethnic%20Diversity%20of%20DPD%20Activity%20and%20the%20DPYD%20Gene:%20Review%20of%20the%20Literature&rft.jtitle=Pharmacogenomics%20and%20personalized%20medicine&rft.au=White,%20Cassandra&rft.date=2021-01-01&rft.volume=14&rft.spage=1603&rft.epage=1617&rft.pages=1603-1617&rft.issn=1178-7066&rft.eissn=1178-7066&rft_id=info:doi/10.2147/PGPM.S337147&rft_dat=%3Cgale_doaj_%3EA689558203%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c576t-9ccb0dd622f3a6fb3495333220c5eacf8cdee08b3dcb8fa2942c4c4de5b45ec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2611006330&rft_id=info:pmid/34916829&rft_galeid=A689558203&rfr_iscdi=true